Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease thrombocytopenia
Phenotype C0027947|neutropenia
Sentences 29
PubMedID- 24299473 Evans syndrome (es) is a rare hematological disease commonly defined by the combination of simultaneous or sequential autoimmune hemolytic anemia (aiha) and immune thrombocytopenia (itp) sometimes associated with neutropenia in the absence of known underlying etiology.
PubMedID- 21278245 The most common grade 3 or higher adverse events were neutropenia (49% of patients), thrombocytopenia (16%), fatigue (16%), lymphopenia (14%), and febrile neutropenia (7%).
PubMedID- 21455428 [9–11] typically, the platelet count falls to 80% of the normal and thrombocytopenia may be associated with neutropenia and anemia.
PubMedID- 20556612 Grade 3–4 hematologic toxicities included neutropenia in 51.0% of patients, thrombocytopenia in 2.0%, and anemia in 20.4%.
PubMedID- 23812930 Grade 3-4 hematologic adverse events were: neutropenia in 28% of the courses, thrombocytopenia in 9%, and anemia in 3%.
PubMedID- 23788967 The most common hematologic adverse events were neutropenia (20% of cycles) and thrombocytopenia (4%), with grade 3/4 incidence of 8% and 1.5% [according to national cancer institute common toxicity criteria (nci ctc)].
PubMedID- 21783417 Chemotherapy was associated with more grade 3 or 4 toxic effects than was erlotinib (including neutropenia in 30 [42%] of 72 patients and thrombocytopenia in 29 [40%] patients on chemotherapy vs no patients with either event on erlotinib); the most common grade 3 or 4 toxic effects with erlotinib were increased alanine aminotransferase concentrations (three [4%] of 83 patients) and skin rash (two [2%] patients).
PubMedID- 26413372 If patients experience grade 4 febrile neutropenia (fever of 38.5°c) or thrombocytopenia that requires platelet transfusion, treatment with romidepsin should be delayed.
PubMedID- 20187098 The main grade 3/4 toxicity was neutropenia in 18% of cycles followed by thrombocytopenia in 9% of cycles, nausea/vomiting in 5% of cycles, and febrile neutropenia, fatigue, anemia, and stomatitis in 2% of cycles.
PubMedID- 25042202 The most common grade 3 or greater adverse events included neutropenia (73% [24 of 33 patients]), thrombocytopenia (21% [seven patients]), and febrile neutropenia and anaemia (18% each [six patients]).
PubMedID- 26090398 The most common grade ≥3 toxicities observed were neutropenia in 85.2% of the cycles, thrombocytopenia in 25.2%, febrile neutropenia in 25.2%, neutropenic enterocolitis in 6%, and mucositis in 5.2%.
PubMedID- 25027517 The main dose-limiting ae was neutropenia, and all cases of neutropenia and thrombocytopenia were reversible and manageable.
PubMedID- 26229484 This increased proliferation leads to cytopenias, which commonly present with neutropenia leading to infections, thrombocytopenia leading to bleeding complications, and anemia presenting as dyspnea on exertion or at rest.1 the incidence of aml increases with age, with the median age of diagnosis being 65–70 years.2 the cytopenias and the elderly age at presentation complicate the treatment with standard induction, showing very poor survival at 2 years.2 even for patients of younger age (<60 years), the standard-of-care treatments have not changed significantly for the better in the past.
PubMedID- 21458256 Grade 3-4 toxicities included neutropenia in 83% of patients, thrombocytopenia in 47%, anaemia in 60%, infection in 23%, and diarrhoea in 20%.
PubMedID- 23482784 Grade 3/4 toxicity encountered during the first cycle included g3/g4 neutropenia in 65% of patients (12/14), g3/g4 thrombocytopenia in 48% (18/1), g3 febrile neutropenia in 5% (2), g3 nausea in 5% (2), g3 diarrhea in 5% (2), and g3 fatigue in 5% of patients (2).
PubMedID- 21949519 Thus, vsga or sga infants are particularly vulnerable to bleeding with thrombocytopenia or infection associated with neutropenia especially early after birth.
PubMedID- 24535315 Transient neutropenia (50 % of patients) and thrombocytopenia (33-38 %) were the most common severe hematological abnormalities; their incidence was higher than with single-agent pm00104.
PubMedID- 22993584 Grade 3-4 neutropenia occurred in 57% of patients, thrombocytopenia and anemia in 2% of cases.
PubMedID- 19652971 Grade 3/4 toxicities included neutropenia (33.9% of patients) and thrombocytopenia (7.6%).
PubMedID- 21116412 Dose limiting toxicities according to the manufacturer’s spc: anc < 500/μl for more than five days or neutropenia associated with fever/infection; thrombocytopenia < 25.000/μl; bilirubin > uln; ap > 2.5× uln; ast/alt > 2.5× uln.
PubMedID- 25031949 Familiarity with factors predictive of high-risk febrile neutropenia, bleeding due to thrombocytopenia, and cardiopulmonary compromise due to anemia will provide the advanced practitioner (ap) in oncology with critical tools for rapid identification of patients at risk, prompt implementation of established guidelines for management, and avoidance of clinical deterioration.
PubMedID- 23782157 Grade 3 or higher hematologic events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%).
PubMedID- 24155675 Overall adverse events according to ctcae v.3.0 during chemotherapy are shown in table 4. the most common grade 3/4 hematologic toxicity was neutropenia, with an incidence of 12%, followed by thrombocytopenia (10%).
PubMedID- 21610706 Dose-limiting toxicities consisted exclusively of myelosuppression (neutropenia with or without thrombocytopenia), leading to a delay in initiation of cycle 2 dosing.
PubMedID- 22162923 Important drug-related toxicities include grade ≥3 neutropenia (43% of patients) and thrombocytopenia (13% of patients).
PubMedID- 22937307 Typical disease manifestations include fatigue and weakness from anemia, infections from neutropenia, or bleeding due to thrombocytopenia or platelet dysfunction.
PubMedID- 22941346 Grade 3 or higher toxicity included neutropenia in 17.9 % of the patients, thrombocytopenia in 5.1 % and nausea in 7.7 %.
PubMedID- 20178634 Wiskott-aldrich syndrome is an x-linked disorder characterized by current infection, thrombocytopenia (with small platelets), neutropenia, eczema, high ige levels, a very high prevalence of autoimmunity (including arthropathy, vasculitis, and inflammatory bowel disease) and malignancy.
PubMedID- 24611018 Erlotinib was associated with less grade 3 or 4 toxic effects than chemotherapy (including neutropenia in 30 of 72 patients and thrombocytopenia in 29 patients on chemotherapy versus no patients with either event on erlotinib); the most common grade 3 or 4 toxic effects with erlotinib were increased alanine aminotransferase concentrations (4%, three of 83) and skin rash (2%, two of 83).

Page: 1